Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBITDA: 2012-2024

Historic EBITDA for Ascendis Pharma A (ASND) over the last 13 years, with Dec 2024 value amounting to -$408.1 million.

  • Ascendis Pharma A's EBITDA fell 1188.00% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.7 million, marking a year-over-year increase of 53.89%. This contributed to the annual value of -$408.1 million for FY2024, which is 21.67% up from last year.
  • As of FY2024, Ascendis Pharma A's EBITDA stood at -$408.1 million, which was up 21.67% from -$520.9 million recorded in FY2023.
  • In the past 5 years, Ascendis Pharma A's EBITDA registered a high of -$408.1 million during FY2024, and its lowest value of -$595.3 million during FY2022.
  • For the 3-year period, Ascendis Pharma A's EBITDA averaged around -$508.1 million, with its median value being -$520.9 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 219,296.12% in 2020, then increased by 21.67% in 2024.
  • Ascendis Pharma A's EBITDA (Yearly) stood at -$478.4 million in 2020, then grew by 9.20% to -$434.4 million in 2021, then crashed by 37.05% to -$595.3 million in 2022, then climbed by 12.50% to -$520.9 million in 2023, then rose by 21.67% to -$408.1 million in 2024.